CD163 and neoplasm: To further confirm this conclusion in the context of anti-PD-1 plus chemotherapy, primary tumor samples from gastric cancer patients treated with the neoadjuvant anti-PD-1 plus chemotherapy combination were collected and stained against proMBP1 and CD163.